Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Spain ETF (EWP) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Ishares Msci Spain ETFTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Spain ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Ishares Msci Spain ETF trades at $59.16, while Regeneron Pharmaceuticals Inc trades at $679.95 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

EWPREGN
Sector
Broad Market / FactorHealth
52-Week High
$60.28$812.27
52-Week Low
$43.90$542.52
Market Cap
$69.66B
Enterprise Value
$63.61B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Spain ETF

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.

Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Spain ETF

EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.

Read more on EWP

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN